Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074

NCT02957617 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

302

Enrollment

INDUSTRY

Sponsor class

Stopped The parent study did not meet its primary or secondary efficacy endpoints and therefore Sponsor decision to discontinue development in this indication.

Conditions

Neuropathic Pain From Lumbosacral Radiculopathy

Interventions

DRUG: BIIB074

Sponsor

Biogen